Chia-Feng Lu joins Greenberg Traurig as shareholder

13 October 2020

Chia-Feng Lu joins Greenberg Traurig as shareholder

Chia-Feng Lu has joined Greenberg Traurig as a shareholder in its health care and FDA practice and its life sciences and medical technology group. The firm said in a release that he will spend most of his time in its Washington office and in Tokyo and Osaka, and will also regularly visit other parts of the United States and Europe.

Lu focuses his multi-national practice on guiding life sciences companies and emerging technology companies in non-life sciences fields through the regulatory and transactional law that applies to their products, technologies, services, and business strategies. He worked on several products based on Nobel-winning science in the past two decades, one of which has successfully reached the blockbuster status.

“Chia-Feng brings a unique perspective that enhances our global capabilities in the health care and FDA space, and adds further depth to our growing Washington, D.C., team,” said Washington shareholder Nancy E. Taylor and and Ft. Lauderdale, Florida-shareholder David C. Peck, who co-chair the firm’s healthcare and FDA practice, in a joint statement. “Greenberg Traurig’s global platform aligns strategically with his practice, and his work in Asia and the U.S. will serve as an important resource to our clients.”

Lu, who represents clients expanding to Asia, also regularly assists companies entering the U.S. or Europe. He has broad experience and familiarity with business practice; the policy and regulatory systems in Asia, with strong emphasis on North Asia, among others. Lu also sits on a number of advisory committees to the government, and has been an adjunct faculty to medical schools and business schools.

Lu joins the firm from Baker McKenzie. He previously worked for a leading biotechnology company and at a Top 10 pharmaceutical company’s headquarters.

“My work with clients with matters before the regulatory agencies and policy makers in key markets will prove valuable for clients facing uncertain regulatory hurdles during their global business planning. Because I will be in Washington, D.C., where many policies with global impacts are being made, clients will have direct access to me to navigate those uncharted waters,” Lu said.

Law firms

Please wait while the page is loading...